Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Schweizer

Showing results (171-180 of 267) with videos related to

Pageof 27
Sort By:
Prostate Cancer and Prostatic Diseases|August 21, 2013
Pharmacodynamic study of disulfiram in men with non-metastatic recurrent prostate cancerM T Schweizer, J Lin, A Blackford, et al.
Cancer|August 15, 2013
Adjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501): important lessons for future trialsMichael T Schweizer, Peng Huang, Michael W Kattan, et al.
Plos One|May 27, 2020
Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapiesLaura S Graham, Bruce Montgomery, Heather H Cheng, et al.
The Prostate|February 13, 2023
Clinical, pathologic, and molecular features of amphicrine prostate cancerLaura S Graham, Michael C Haffner, Erolcan Sayar, et al.
The Prostate|September 2, 2014
Clinical activity of enzalutamide in Docetaxel-naïve and Docetaxel-pretreated patients with metastatic castration-resistant prostate cancerRosa Nadal, Zhe Zhang, Hibba Rahman, et al.
European Urology|February 25, 2019
Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM MutationsCatherine H Marshall, Alexandra O Sokolova, Andrea L McNatty, et al.
JCO Precision Oncology|September 19, 2025
Prognostic Significance of <i>RB1</i> Alterations on Outcomes in Metastatic Prostate CancerRuben Raychaudhuri, Isla P Garraway, Kara N Maxwell, et al.
European Urology|June 18, 2024
Docetaxel and Carboplatin for the Treatment of Patients with Metastatic Castration-resistant Prostate Cancer and Biallelic Inactivation of Genes in the Homologous Recombination DNA Repair Pathway: The ABCD TrialRuben Raychaudhuri, Makayla DeJong, Matthew Rettig, et al.
JAMA Oncology|June 4, 2021
Concordance of DNA Repair Gene Mutations in Paired Primary Prostate Cancer Samples and Metastatic Tissue or Cell-Free DNAMichael T Schweizer, Smruthy Sivakumar, Hanna Tukachinsky, et al.
Histopathology|December 12, 2025
Molecular subtypes of metastatic prostate cancer: from pathophysiology to diagnosisJeanne M Dsouza, Erolcan Sayar, Michael T Schweizer, et al.
Pageof 27

Showing results (171-180 of 267) with videos related to

Sort By:
Pageof 27
Prostate Cancer and Prostatic Diseases|August 21, 2013
Pharmacodynamic study of disulfiram in men with non-metastatic recurrent prostate cancerM T Schweizer, J Lin, A Blackford, et al.
Cancer|August 15, 2013
Adjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501): important lessons for future trialsMichael T Schweizer, Peng Huang, Michael W Kattan, et al.
Plos One|May 27, 2020
Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapiesLaura S Graham, Bruce Montgomery, Heather H Cheng, et al.
The Prostate|February 13, 2023
Clinical, pathologic, and molecular features of amphicrine prostate cancerLaura S Graham, Michael C Haffner, Erolcan Sayar, et al.
The Prostate|September 2, 2014
Clinical activity of enzalutamide in Docetaxel-naïve and Docetaxel-pretreated patients with metastatic castration-resistant prostate cancerRosa Nadal, Zhe Zhang, Hibba Rahman, et al.
European Urology|February 25, 2019
Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM MutationsCatherine H Marshall, Alexandra O Sokolova, Andrea L McNatty, et al.
JCO Precision Oncology|September 19, 2025
Prognostic Significance of <i>RB1</i> Alterations on Outcomes in Metastatic Prostate CancerRuben Raychaudhuri, Isla P Garraway, Kara N Maxwell, et al.
European Urology|June 18, 2024
Docetaxel and Carboplatin for the Treatment of Patients with Metastatic Castration-resistant Prostate Cancer and Biallelic Inactivation of Genes in the Homologous Recombination DNA Repair Pathway: The ABCD TrialRuben Raychaudhuri, Makayla DeJong, Matthew Rettig, et al.
JAMA Oncology|June 4, 2021
Concordance of DNA Repair Gene Mutations in Paired Primary Prostate Cancer Samples and Metastatic Tissue or Cell-Free DNAMichael T Schweizer, Smruthy Sivakumar, Hanna Tukachinsky, et al.
Histopathology|December 12, 2025
Molecular subtypes of metastatic prostate cancer: from pathophysiology to diagnosisJeanne M Dsouza, Erolcan Sayar, Michael T Schweizer, et al.
Pageof 27